Sir Gregory Winter is the most recent former Master of Trinity College Cambridge and until recently a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge. He is a scientist, inventor and entrepreneur. His scientific career has almost entirely been based in Cambridge where his work has involved the development of technologies for making pharmaceutical antibodies by genetic engineering. Such antibodies have proved useful for treatment of cancer and immune disorders, and now comprise many of the world’s top selling pharmaceutical drugs. These include the “humanized” antibodies Herceptin (for treatment of breast cancer) and Lucentis (for treatment of wet acute macular degeneration), and the human antibody Humira (for treatment of rheumatoid arthritis), currently the world’s top selling pharmaceutical drug.
In order to advance his discoveries, Sir Gregory has founded several successful start-up companies, including Cambridge Antibody Technology in 1990 (acquired by Astra Zeneca in 2006), Domantis in 2000 (acquired by GSK in 2006) and Bicycle Therapeutics in 2010, which is developing a peptide product for the treatment of cancer. He is a Trustee of the Kennedy Trust for Rheumatology Research, non-executive director of Bicycle Therapeutics and consults to Biosceptre.
Sir Gregory is a Fellow of the Royal Society, has received numerous international prizes and awards, and in 2004 was knighted for his services to Molecular Biology. In 2018 he was awarded the 2018 Nobel Prize in Chemistry.